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Summary 
Objectives. Treatment of chronic epilepsy in acute porphyrias may be difficult 
because many antiepileptic drugs can cause activation of clinically-latent conditions. 
Methods. A 44 year-old lady with drug-resistant chronic epilepsy and a previous 
genetic diagnosis of variegate porphyria was referred to our epilepsy centre. We 
started her on perampanel, a structurally novel selective non-competitive AMPA 
receptor antagonist recently approved for the treatment of partial and secondarily 
generalized seizures in humans. There are no previous reports about the outcome of 
exposure to perampanel of carriers of acute porphyria. 
Results. Perampanel was assessed in silico to be probably not porphyrogenic. 
Administration of the drug up to 4 mg/day did not lead to elevation of urinary 
porphobilinogen excretion, nor to any symptoms of acute porphyria after more than 
23 months of treatment.  
Conclusions. Perampanel up to 4 mg/day was tolerated in long-term therapy in this 
carrier of protoporphyrinogen oxidase deficiency. However, since perampanel is a 
weak inducer of cytochrome P450 enzymes, vigilance should be maintained for 
clinical and biochemical signs of activation of acute porphyria when used in a carrier 
of acute porphyria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Management of epilepsy associated with porphyrias - what to use and what not 
to use (http://www.drugs-porphyria.org, accessed 20/10/2015; 
http://www.wmic.wales.nhs.uk/pdfs/porphyria/2015%20Porphyria%20safe%20l
ist.pdf, accessed 20/10/2015). 
Acute symptomatic seizures occur in approximately 10–20% of patients with acute 
intermittent porphyria in relapse, while there are rarer reports of porphyria in people with 
chronic epilepsy, mostly drug-resistant. The association between epilepsy and porphyria is 
unclear. Porphyria might be the cause of chronic symptomatic epilepsy (if so, this would be 
rare or frequently undiagnosed) or there might be a chance association, given that epilepsy is 
common. Nevertheless, in drug-resistant epilepsy, metabolic causes such as the porphyrias 
need to be considered, especially when the seizure frequency increases on higher doses of 
certain antiepileptic drugs (AEDs). Acute porphyric attacks can be potentially fatal and such 
attacks are usually precipitated, in susceptible individuals, by exposure to commonly 
used drugs, including certain AEDs. Correctly determining the safety of use of certain 
drugs in people with porphyria is therefore important. Once the diagnosis of porphyria-related 
seizures is confirmed, treatment of the porphyria itself will be needed: management will 
include appropriate selection of a non-porphyrinogenic AED (as the induction of hepatic 
haemosynthesis by enzyme-inducing AEDs can exacerbate the symptoms of porphyria, or 
bring on acute attacks). 
Clinical experience, and findings from experimental systems, using whole animal or cell 
culture models, have been used to determine porphyrogenicity (the potential of a drug to 
induce an acute porphyric attack) and to classify drugs as safe or unsafe in freely available 
drug lists  (e.g. http://www.drugs-porphyria.org; 
http://www.wmic.wales.nhs.uk/pdfs/porphyria/2015%20Porphyria%20safe%20list.pdf). 
In acute porphyric attacks, seizures can be treated with intravenous diazepam, levetiracetam, 
or propofol if status epilepticus develops; a single or few seizures may not require AED 
treatment in the long term, provided the porphyria itself is properly managed. 
Antiepileptic drugs that are considered 
to be SAFE for use in the acute 
porphyrias (not porphyrinogenic or 
probably not porphyrinogenic) 
 
Clobazam 
Clonazepam  
Gabapentin  
Lacosamide 
Lamotrigine  
Levetiracetam  
Paraldehyde  
Piracetam 
Pregabalin 
Retigabine 
Vigabatrin 
Zonisamide 
 
Antiepileptic drugs that should not be 
used in the acute porphyrias 
(porphyrinogenic or probably 
porphyrinogenic) 
 
Carbamazepine 
Ethosuximide 
Felbamate 
Oxcarbazepine 
Phenobarbital 
Phenytoin 
Primidone 
Stiripentol 
Tiagabine 
Topiramate 
Valproic acid 
 
Uncertain (possibly porphyrinogenic or not yet classified) 
Acetazolamide  
Eslicarbazepine 
Perampanel 
Rufinamide 
 
Background 
 
The porphyrias form a heterogeneous group of inherited metabolic disorders, each of 
which results from deficiency of a specific enzyme in the multi-step heme 
biosynthetic pathway. [1]  
 
Variegate porphyria (VP) is an autosomal dominant form of hepatic porphyria  
associated with disease-predisposing mutations in the gene for protoporphyrinogen 
oxidase (PPOX). The phenotypic expression of the condition is the result of 
deficiency of this enzyme, which converts protoporphyrinogen to protoporphyrin in 
the penultimate step of heme biosynthesis. 
 
In PPOX-deficiency, the gene carrier state is generally clinically quiescent, but 
symptoms of variegate porphyria can be triggered by exposure to a variety of 
precipitating factors, including a wide range of commonly-prescribed medications. 
Attacks in acute porphyria mainly feature gastrointestinal and neuropsychiatric 
symptoms. Accumulation of phototoxic porphyrins in the skin may give rise to solar 
hypersensitivity and bullous dermal lesions. The treatment of epilepsy in acute 
porphyrias represents a challenge, because many commonly-used antiepileptic drugs 
strongly induce heme-dependent cytochromes P450 in the liver. In the course of 
holoenzyme assembly, the demands for heme are met by the liver through 
acceleration of de novo heme biosynthesis. In PPOX-deficiency, on porphyrogenic 
challenge the pathway may become overloaded, with resulting accumulation of 
phototoxic porphyrins, as well as presumably neurotoxic pre-porphyrin intermediates.  
 
Perampanel is a structurally novel, selective non-competitive AMPA receptor 
antagonist recently approved for the treatment of partial and secondarily generalized 
seizures in humans. We describe a case of epilepsy in a carrier of variegate porphyria, 
in which perampanel was tried after safety assessment. 
 
Case presentation 
This 44 year-old lady was the product of a normal pregnancy and delivery. Her motor 
and cognitive development were normal. Onset of seizures was at nine years of age, 
with a tonic-clonic seizure. She has tried many antiepileptic drugs in the past without 
full seizure control. At age 29, variegate porphyria was diagnosed following 
development of a right hemiparesis with ataxic features and dysphasia. DNA analysis 
showed a deletion [IVS5-(24-16) del CTTAGTCCT] in intron 5 of the PPOX gene, 
likely to be the cause of her variegate porphyria. She was also diagnosed with primary 
hypothyroidism. At 31, a vagal nerve stimulator was implanted, without benefit. She 
was also treated with GnRH analogues and low doses of oestrogens, given some 
correlation between her menstrual cycle and seizure frequency. 
 
She was referred to our centre aged 42. At that time, her antiepileptic medication was 
gabapentin, levetiracetam, pregabalin and clobazam, all previously assessed not to be 
porphyrogenic.  She was experiencing multiple seizures daily, of a variety of types. 
There was no report of her previous or current antiepileptic medication precipitating 
any porphyric crisis. Prolonged EEG-videotelemetry showed interictal abnormalities 
in the left fronto-temporal region, although some right-sided epileptiform changes 
were present. Multiple seizures were captured and electroclinical evidence suggested 
left fronto-temporal origin. Her ECG was normal. Neuropsychometry showed 
widespread cerebral dysfunction, with verbal and visuo-spatial skills falling below the 
average range and verbal memory, naming and fluency all falling within the 
borderline-to-impaired range.  
 
We introduced lacosamide, considered safe in porphyria. Unfortunately she developed 
a skin rash, without associated symptoms of a porphyric crisis. We could not exclude 
an allergy to lacosamide and it was therefore discontinued. 
 
Perampanel is amongst the newest antiepileptic drugs. To our knowledge, there is no 
previous report of its use in acute porphyrias and no patient exposure data were 
available in the National Acute Porphyria Service 
(http://www.cardiffandvaleuhb.wales.nhs.uk/national-acute-porphyria-service-naps, 
accessed 15/03/2013).  
 
Further enquires were made at the Porphyria Centre in Sweden, where perampanel 
was categorized as “probably not porphyrogenic”, considered to be the lowest risk 
category after “safe”. The classification was reached by way of in silico analysis.[4], 
where pharmacokinetic data are used for assessment of drug cytochrome (CYP)-
inductive power. In addition, pharmacodynamic mechanisms, physiological actions 
and side effects of the drug were evaluated for potential capacity for activation or co-
activation of nuclear receptors responsible for CYP-induction. The only finding of 
possible relevance was evidence of weak capacity for CYP3A4 induction, but it was 
not expected to be of a strength to be significant in the present context. There have 
been no reports of clinical observations against in silico safety assessment results. 
 
After discussion with the patient, we started perampanel, with monitoring of urinary 
porphobilinogen. Her urinary porphobilinogen level pre-treatment and at one and two 
weeks on treatment were normal. The National Acute Porphyria Service did not 
recommend further routine urinary monitoring. The dose of perampanel was initially 
2 mg nocte and was gradually titrated in increments of 2 mg up to 4 mg daily. 
 
She had an initial improvement in seizure frequency with up to fifteen days without 
any seizures, compared to daily seizures before perampanel. After about three 
months, she developed unsteadiness and had difficulty transferring from her 
wheelchair. This adverse effect required admission to hospital and physiotherapy. The 
dose of perampanel was subsequently reduced to 2 mg daily. She did not develop any 
symptoms of acute porphyria while on perampanel during 23 months of treatment. 
 
 
Discussion 
While acute symptomatic generalised seizures are recognized features of acute attacks 
of porphyria the association between porphyria and drug-resistant epilepsy is less 
clear, with few reported cases.[2] 
 In the treatment of epilepsy in acute porphyrias, the choice of drugs should be from 
amongst the non-CYP-inducing antiepileptic drugs [see Box above] so that 
porphyrogenic acceleration of hepatic heme biosynthesis is avoided. Treatment with 
the strong CYP-inducers carbamazepine, phenobarbitone, phenytoin, primidone, 
topiramate, and sodium valproateshould be avoided as far as possible. Tiagabine 
shows evidence of porphyrinogenicity in in vitro studies using cultured liver cells and 
may be hazardous. 
The use of perampanel in the present case of variegate porphyria and drug-resistant 
epilepsy was not followed by any clinical or biochemical signs of activation of the 
disorder. A single observation of tolerance to a drug in a carrier of acute porphyria, 
however, cannot be taken as proof of non-porphyrogenicity, because of the great 
variability between carriers, as well as in one carrier over time, in susceptibility to the 
action of porphyria precipitating agents. Women are more prone than men to attacks 
of acute porphyria, and in the present case the carrier exposed to perampanel is a 
female with a history of clinically manifest acute porphyria, indicating that she does 
not belong to the group of individuals seemingly constitutionally resistant to the 
phenotypic manifestations of acute porphyria. The circumstance that our patient is 
potentially vulnerable to porphyrogenic challenge serves to enhance the significance 
of the observation of her tolerance to perampanel, and helps to validate the in silico 
assessment of probable non-porphyrogenicity of the drug.  
 
Recently, two cases with drug-resistant epilepsy in non-carriers of acute porphyria 
have been described in the literature. Both presented in convulsive status epilepticus 
and were on treatment with perampanel. Both patients were found to have 
significantly decreased blood levels of concurrent antiepileptic medication 
(phenytoin, phenobarbital, rufinamide) in comparison with levels prior to perampanel 
introduction. In one of the cases, further increasing the perampanel dose resulted in a 
further drop of the phenytoin level. As demonstrated in cultured human hepatocytes 
and through drug interaction studies, perampanel is weak inducer of CYP2B6 and 
CYP3A4/5, as well as of uridine 5'-diphospho-glucuronosyltransferase, while drug 
transporters are not affected. It is therefore conceivable that the increased rate of 
elimination of the CYP-metabolized co-administered drugs in the reported cases is an 
effect of the weak CYP-inductive capacity of perampanel. Until more experience is 
acquired, initial monitoring of urinary porphobilinogen excretion and subsequent 
clinical vigilance should be routine in the use of perampanel in acute porphyrias, 
especially with higher dosage regimes. Monitoring of concomitant antiepileptic drug 
levels is also indicated. The common side effects, nausea and disturbed appetite, 
would motivate some attention to nutrition of the patient, to reduce risk for potentially 
porphyrogenic decrease of caloric intake. 
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Disclaimer 
In the report, the classifications given for drugs in terms of porphyrogenicity/non-
porphyrogenicity are from the literature and generally based on clinical observations, 
and experimental or in vitro findings. In some cases, they are results of 
pharmacological considerations applied to a genometabolic model of acute porphyria. 
There are, however, potential souces of error in all presently available techniques for 
drug porphyrogenicity assessment. Even with care taken to eliminate them errors lege 
artis, it is not possible to take legal responsibility for the drug classifications provided 
and the data should not be taken as advice . 
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